These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 363702)

  • 1. High vs standard dosage fluphenazine HCL in acute schizophrenia.
    Donlon PT; Meadow A; Tupin JP; Wahba M
    J Clin Psychiatry; 1978 Nov; 39(11):800-4. PubMed ID: 363702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethopropazine and benztropine in neuroleptic-induced parkinsonism.
    Chouinard G; Annable L; Ross-Chouinard A; Kropsky ML
    J Clin Psychiatry; 1979 Mar; 40(3):147-52. PubMed ID: 33969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
    Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
    Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haloperidol in acute schizophrenic inpatients. A double-blind comparison of two dosage regimens.
    Modestin J; Toffler G; Pia M; Greub E
    Pharmacopsychiatria; 1983 Jul; 16(4):121-6. PubMed ID: 6356177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR; Levine J
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients.
    Iqbal MJ; Young MA; Charles J; Elgart B; Von Greiff H; Simpson GM
    J Clin Psychiatry; 1978 Apr; 39(4):375-9. PubMed ID: 580285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of lergotrile on schizophrenia & drug induced parkinsonism.
    Small JG; Kellams JJ; Milstein V; Klapper M; Lemberger L
    Commun Psychopharmacol; 1977; 1(5):461-7. PubMed ID: 23919
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness of oral and parenteral rapid neuroleptization.
    Coffman JA; Nasrallah HA; Lyskowski J; McCalley-Whitters M; Dunner FJ
    J Clin Psychiatry; 1987 Jan; 48(1):20-4. PubMed ID: 3542982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial].
    Woggon B; Dick P; Fleischhauer HJ; Gmür M; Gruber G; Angst J; Heimann H
    Int Pharmacopsychiatry; 1977; 12(4):193-209. PubMed ID: 22515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Disagreement in standardized haloperidol treatment in comparison with "adequate individual dosage" of acutely schizophrenic patients].
    Klieser E; Lehmann E
    Fortschr Neurol Psychiatr; 1992 Mar; 60(3):126-9. PubMed ID: 1577361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dosage piperacetazine (Quide) in ambulatory schizophrenic patients--therapeutic efficacy and toxicity.
    Donlon PT; Rada RT
    Dis Nerv Syst; 1974 May; 35(5):231-6. PubMed ID: 17894106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
    Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
    J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computerized EEG: predictor of outcome in schizophrenia.
    Itil TM; Marasa J; Saletu B; Davis S; Mucciardi AN
    J Nerv Ment Dis; 1975 Mar; 160(3):118-203. PubMed ID: 1090708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controlled study of neuroleptization with fluphenazine hydrochloride injections.
    Escobar JI; Barron A; Kiriakos R
    J Clin Psychopharmacol; 1983 Dec; 3(6):359-62. PubMed ID: 6139394
    [No Abstract]   [Full Text] [Related]  

  • 18. Factors determining patient tenure on a 3-year double-blind investigation of pimozide versus fluphenazine HCl.
    Abuzzahab FS; Zimmermann RL
    Adv Biochem Psychopharmacol; 1980; 24():547-50. PubMed ID: 7405675
    [No Abstract]   [Full Text] [Related]  

  • 19. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.